Upadacitinib

Overview

Upadacitinib is an oral Janus kinase (JAK) inhibitor used for the treatment of several autoimmune disorders. It helps in reducing inflammation by targeting specific pathways involved in the inflammatory response.

API suppliers (9)

Suppliers of Upadacitinib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• CURIA SPAIN SAUSpain1 active DMF GMP on record
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
• MSN Laboratories Private LimitedIndia1 active DMF GMP on record
• HOSTER LABS PRIVATE LTDIndia1 active DMF GMP on record
• CRYSTAL PHARMACEUTICAL SUZHOU CO LTD1 active DMF
• LEE PHARMA LTDIndia1 active DMF GMP on record
• SICHUAN GOWELL PHARMACEUTICAL CO LTD1 active DMF
• CHANGZHOU PHARMACEUTICAL FACTORYChina1 active DMF GMP on record
• Shanghai Desano Chemical Pharmaceutical Co., LtdChina1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (4 approved US products), the latest listed US patent on Upadacitinib expires 9 Mar 2038 and exclusivity 28 Apr 2032. Generic API sourcing typically opens up once these lapse.

Therapeutic areas